STAAR Surgical (STAA) Q1 2025: China Revenue Plunges 99% as Inventory Burn Drives Channel Reset

May 7, 2025 | By EarningsIQ Research

STAAR Surgical’s Q1 was defined by a near-total collapse in reported China sales as distributors consumed inventory, while global ex-China growth signaled underlying demand resilience. Management’s decisive tariff mitigation, cost cuts, and Swiss manufacturing ramp set up a pivotal second-half inflection, but execution risk remains high as formal guidance is withdrawn.

Summary

• China Channel Reset: Reported China revenue collapsed as distributors worked down inventory, masking stable in-market procedure volumes.
• Cost Discipline and Tariff Maneuvering: Management enacted aggressive cost cuts and consignment inventory shifts to offset tariff exposure and improve cash flow trajectory.
• Second-Half Rebound Hinges on Execution: Normalized China sales, Swiss capacity ramp, and new product launches must deliver amid ongoing macro and regulatory volatility.

Performance Analysis

STAAR Surgical’s Q1 headline was a 99% year-over-year decline in reported China sales, falling from $38.5 million to just $389,000 as China distributors drew down prior inventory rather than placing new orders. This single-country collapse drove total net sales down to $42.6 million from $77.4 million last year. However, sales outside China rose 9%, led by APAC (ex-China), EMEA, and Americas growth—all contributing to a more robust underlying demand picture than the consolidated number suggests.

Gross margin compressed sharply to 65.8% (from 78.9%), primarily due to lower production volumes in the US, start-up costs in Switzerland, and higher inventory reserves. Adjusted EBITDA swung to a $26.4 million loss, reflecting the impact of restructuring charges and the steep gross profit drop. Management highlighted that cash burn will trough in Q2/Q3 but expects profitability and positive cash flow to return in the second half as inventory normalization and cost reductions take effect.

• China Inventory Overhang: Distributors’ inventory drawdown masked steady in-market procedures, setting up a Q3 sales rebound as channel clears.
• Global Growth Engines: Ex-China regions delivered 9% YoY growth, with Japan, South Korea, and India leading APAC momentum.
• Margin Compression Drivers: Ramp-up costs in Switzerland and underutilized US facilities weighed on gross margin, with recovery dependent on higher output and efficiency.

Restructuring and cost actions are expected to lower SG&A run rate to $225 million by year-end, returning the company to pre-2023 expense levels and supporting a return to profitability as sales recover.

Executive Commentary

Strategic Positioning

1. China: Channel Reset and Tariff Navigation

STAAR Surgical undertook a deliberate channel inventory reset in China, prioritizing long-term demand integrity over short-term revenue recognition. With consignment inventory now in-country and distributors nearing contractual inventory levels, the company expects reported sales to realign with actual procedure volumes in Q3. The rapid deployment of consignment stock ahead of tariff deadlines mitigates near-term geopolitical risk, and the Swiss manufacturing ramp provides a strategic hedge for 2026 and beyond.

2. Cost Structure Realignment

The company is executing a comprehensive cost reduction plan, including workforce reductions, facility rationalization, and marketing spend cuts—primarily in the US, which remains a small share of global sales. The SG&A run rate target of $225 million by year-end is designed to reinforce, not constrain, growth ambitions, with management emphasizing a return to 2023 expense levels without undermining operational capability.

3. Swiss Manufacturing Expansion

Ramp-up of the Swiss facility is central to both tariff mitigation and future supply flexibility. Once validated, the site will supply over 300,000 lenses annually by end-2026, with long-term potential exceeding 800,000. This capacity is crucial for de-risking China exposure and supporting global growth as demand for EVO-ICL, STAAR’s proprietary implantable lens, rises.

4. Product Pipeline and Market Access

Approval of the EVO Plus (V5) lens in China, expected this summer, marks the first new lens launch in the region in over a decade. Expanded labeling in Brazil and ongoing regulatory efforts in other markets are broadening the addressable market, with pricing strategies under review to maximize value capture across geographies.

5. Leadership and Transparency Reset

New CEO Steve Farrell and a revamped executive team have prioritized transparency and operational discipline, resetting investor expectations by withdrawing formal guidance yet providing detailed scenario commentary on revenue, margins, and cash. The leadership is focused on restoring credibility and aligning resource allocation with market opportunity.

Key Considerations

STAAR’s Q1 was a turning point, with management balancing tactical crisis management and long-term strategic pivots. Investors should focus on the following:

Key Considerations:

• Channel Inventory Dynamics: The pace of inventory normalization in China will dictate the timing and magnitude of reported revenue rebound in Q3 and beyond.
• Tariff and Geopolitical Risk: The effectiveness of Swiss manufacturing as a tariff hedge is critical, especially if trade tensions persist into 2026.
• Margin Recovery Path: Gross margin restoration depends on scaling new capacity, reducing period costs, and managing obsolete inventory risk.
• Execution on Cost Cuts: Realizing SG&A reductions without impairing growth initiatives, especially in the US and emerging markets, remains a delicate balance.
• Product Innovation and Market Access: Successful launch and adoption of EVO Plus in China and expanded labeling in Brazil are key to unlocking new growth vectors.

Risks

STAAR Surgical faces elevated risk from China macro volatility, evolving tariff regimes, and potential delays in Swiss manufacturing validation. The withdrawal of formal guidance underscores management’s caution amid unpredictable policy shifts. Execution risk is heightened by the need to simultaneously manage cost discipline, supply chain complexity, and new product launches.

Forward Outlook

For Q2, management expects continued inventory normalization in China, with reported sales remaining below in-market demand until Q3. No formal guidance was provided, but management commentary suggests:

• Ex-China sales growth in the high-single to low-double digits for the year
• China sales to rebound in Q3 as consignment inventory is recognized
• SG&A run rate to exit 2025 at $225 million
• Gross margin to improve in 2H25 but remain below historical highs

Leadership cited high confidence in a second-half sales and profitability rebound, contingent on execution of inventory and cost actions, as well as successful Swiss facility validation.

• Inventory levels in China will reach contractual norms by end of Q2
• Swiss manufacturing to be validated and producing for China by summer

Takeaways

STAAR’s Q1 results reflect a business in transition, with underlying demand signals masked by channel inventory shifts and macro headwinds. Strategic moves in supply chain and cost structure position the company for recovery, but execution risk remains elevated.

• Inventory-Driven Volatility: Reported revenue volatility in China is transitory, but underscores the need for better channel visibility and agile supply chain management.
• Cost and Margin Discipline: SG&A and gross margin recovery are necessary for sustained cash flow and valuation support as top-line growth resumes.
• Future Watchpoint: Investors should monitor Q3 China sales normalization, Swiss facility ramp, and EVO Plus adoption as leading indicators of recovery strength.

Conclusion

STAAR Surgical is navigating a complex reset, with short-term pain in reported results setting the stage for a potential second-half rebound. Success will require flawless execution on channel, cost, and supply chain initiatives as the company seeks to restore growth and profitability credibility.

Industry Read-Through

STAAR’s China-driven revenue collapse and rapid channel adjustment highlight the risks of distributor inventory build-up and geopolitical exposure for all medtech players in China. The company’s shift to consignment and local manufacturing mirrors strategies seen across the sector as trade tensions intensify. The lens-based refractive market continues to outpace legacy laser procedures, but margin compression and regulatory volatility will test all players. Competitors and suppliers should expect continued inventory volatility, shifting pricing strategies, and a premium on supply chain agility as the market evolves.

STAA Health Care Medical Devices Ophthalmology China Tariffs Inventory Cost Cutting